Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

As we learn more about the deadly midair collision between a passenger jet and military helicopter in Washington, D.C., military officials are joining the search for clues that will help determine ...

In the Spanish city of Murcia, an explosion occurred at the plant of the German company Rheinmetall, which manufactured ...

In imported Lay's chips, traces of six allergens were found at once, which the manufacturer did not inform about on the ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

One of the standout projects making waves in this space is Monsta Mash, a GameFi ecosystem that is drawing significant attention from large investors due to its incredibly low entry price of $0.00365.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...